Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases
Background: In the last years, inflammatory bowel disease (IBD) and hepatitis C virus (HCV) infection management has completely changed. However, the role of direct-acting antivirals (DAAs) and the correct timing of antiviral drugs administration in IBD patients needing biologics has not been evalua...
Main Authors: | Nicola Imperatore, Fabiana Castiglione, Antonio Rispo, Anna Sessa, Nicola Caporaso, Filomena Morisco |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00867/full |
Similar Items
-
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
by: Nancy Abdel Fattah Ahmed, et al.
Published: (2020-08-01) -
Role of different direct-acting antiviral drugs on hepatitis C virus-associated mixed cryoglobulinemia in Egyptian patients
by: Tarek A Elshazly, et al.
Published: (2019-01-01) -
Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C
by: Gao LH, et al.
Published: (2021-01-01) -
Detection of drug resistance mutations of hepatitis C virus in patients with failure of the treatment with direct acting antivirals
by: D. E. Valutite, et al.
Published: (2021-03-01) -
Retrospective Evaluation on Patient Screening and Counseling Service on Direct-acting Antivirals Against Hepatitis C
by: Bob Ka Him Wong, et al.
Published: (2020-05-01)